AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-3.67%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$639M
AUM Growth
+$639M
(-0.21%)
Cap. Flow
+$95.5M
Cap. Flow
% of AUM
14.95%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
109
New
20
Increased
27
Reduced
17
Closed
13
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$16.8M |
| 2 |
Travere Therapeutics
TVTX
|
$15.6M |
| 3 |
Protagonist Therapeutics
PTGX
|
$13.1M |
| 4 |
Nuvalent
NUVL
|
$12.4M |
| 5 |
Mineralys Therapeutics
MLYS
|
$11.9M |
Top Sells
| 1 |
Arvinas
ARVN
|
$12.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$10.3M |
| 3 |
Soleno Therapeutics
SLNO
|
$5.72M |
| 4 |
Arrowhead Research
ARWR
|
$5.64M |
| 5 |
Spyre Therapeutics
SYRE
|
$5.53M |
Sector Composition
| 1 | Healthcare | 90.82% |
| 2 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORKA
26
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $5.6M | 0.53% |
545,362
+176,664
| +48% | +$1.81M |
|
27
Neurocrine Biosciences
NBIX
$13.5B
| $5.53M | 0.53% |
+50,000
| New | +$5.53M |
|
28
Avalo Therapeutics
AVTX
$139M
| $5.26M | 0.5% |
657,154
+106,389
| +19% | +$852K |
|
29
Viridian Therapeutics
VRDN
$1.59B
| $5.26M | 0.5% |
390,000
+230,386
| +144% | +$3.11M |
|
30
Lexeo Therapeutics
LXEO
$266M
| $5.14M | 0.49% |
+1,480,881
| New | +$5.14M |
|
|
31
Crinetics Pharmaceuticals
CRNX
$3.26B
| $5.11M | 0.49% |
152,252
-307,748
| -67% | -$10.3M |
|
32
Rezolute
RZLT
$630M
| $4.93M | 0.47% |
1,700,000
+125,000
| +8% | +$363K |
|
33
Perspective Therapeutics
CATX
$251M
| $4.74M | 0.45% |
2,224,196
+924,196
| +71% | +$1.97M |
|
|
AUTL
34
Autolus Therapeutics
AUTL
$383M
| $4.72M | 0.45% |
3,045,000
-1,455,000
| -32% | -$2.26M |
|
35
Erasca
ERAS
$406M
| $4.58M | 0.44% |
3,341,519
+842,088
| +34% | +$1.15M |
|
36
ProQR Therapeutics
PRQR
$256M
| $4.37M | 0.42% |
3,284,512
+459,512
| +16% | +$611K |
|
37
uniQure
QURE
$954M
| $4.24M | 0.4% |
+400,000
| New | +$4.24M |
|
|
PCSC
38
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $3.62M | 0.35% |
350,000
| – | – |
|
|
39
Soleno Therapeutics
SLNO
$3.56B
| $3.57M | 0.34% |
50,000
-80,000
| -62% | -$5.72M |
|
|
INZY
40
DELISTED
Inozyme Pharma
INZY
| $3.52M | 0.34% |
3,867,710
-104,608
| -3% | -$95.2K |
|
41
Akebia Therapeutics
AKBA
$827M
| $2.88M | 0.27% |
+1,500,000
| New | +$2.88M |
|
|
MAZE
42
Maze Therapeutics, Inc. Common Stock
MAZE
$666M
| $2.75M | 0.26% |
+250,000
| New | +$2.75M |
|
43
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $2.75M | 0.26% |
241,957
+4,022
| +2% | +$45.7K |
|
44
Kymera Therapeutics
KYMR
$3.1B
| $2.74M | 0.26% |
100,000
+60,000
| +150% | +$1.64M |
|
|
OACCU
45
Oaktree Acquisition Corp. III Life Sciences Unit
OACCU
$191M
| $2.6M | 0.25% |
250,000
| – | – |
|
46
Geron
GERN
$893M
| $2.39M | 0.23% |
1,500,000
-750,000
| -33% | -$1.19M |
|
47
Monopar Therapeutics
MNPR
$223M
| $2.26M | 0.22% |
+62,000
| New | +$2.26M |
|
48
Mirum Pharmaceuticals
MIRM
$3.75B
| $2.24M | 0.21% |
49,692
-21,050
| -30% | -$948K |
|
|
JBIO
49
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $2.01M | 0.19% |
800,000
| – | – |
|
50
Cullinan Oncology
CGEM
$456M
| $2M | 0.19% |
263,817
| – | – |
|